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than 10 is signiﬁcant PH above which the complications
like variceal bleed and ascites develop. Currently proposed
classiﬁcation of cirrhosis is based on the degree of PH
and associated clinical features. Development of ascites,
variceal bleed and hepatic encephalopathy is considered
to be decompensated cirrhosis. PH results from increase
in the intrahepatic resistance which has dynamic and ﬁxed
components and it is coupled with increase in the portal
blood ﬂow. Therapeutic interventions which can reduce the
HVPG like non selective beta blockers and Transjugular
intrahepatic porta systemic shunt (TIPS) can be helpful in
combating complications of cirrhosis. And they have been
shown to improve survival. Bacterial infection is common in
cirrhosis with one month mortality of 30%. Oral prophylactic
antibiotics or bowel decontamination have shown to
improve long term outcome in patients with decompensated
cirrhosis. Malnutrition is common in all patients with
cirrhosis. Now it is clear there is no need of restricting
the proteins in these patients. In fact nutritional therapy
can improve survival, reduce the rate of infections, stay in
ICU and hospital, and reduce post operative complications.
Screening for hepatocellular carcinoma (HCC) can pick up
very early disease and survival can be improved in these
patients by offering curative treatment. Therapeutic modal-
ities can reverse the cirrhosis. These modalities according
to the etiology are (1) abstinence for alcoholic cirrhosis,
(2) antiviral therapy for hepatitis B, (3) immunosuppression
for autoimmune hepatitis, (4) relieving biliary obstruction
in patients with secondary biliary cirrhosis, (5) antiviral
therapy for hepatitis C and (6) relieving obstruction in
patients with budd Chiari syndrome. Future therapies like
antiﬁbortic, antiangiogenic and anti coagulants may have
potentials reducing ﬁbrosis, reversing cirrhosis. Stem cell
therapy may be helpful in patients with liver cirrhosis.
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PL-001 USP18 stimulates HCV production in vitro:
a novel mechanism for HCV resistance to
interferon therapy
L.M. Chen1 *, J. Sun1, L.-T. Lin2, M.X. Ma1, C. Richardson2,
A. Edwards1, J. Feld1, I. McGilvray1. 1University of Toronto,
2Dalhousie University, Canada
Background: The molecular mechanisms of interferon
resistance in almost 50% of the HCV infected patients remain
unclear. We have previously identiﬁed that upregulation
of interferon stimulated genes (ISGs), such as Interferon
Stimulated Gene15 (ISG15) and Ubiquitin Speciﬁc Protease
18 (USP18) in hepatocytes, predicts treatment failure.
Moreover, silencing USP18 potentiates IFN anti-HCV activity
and increased expression of ISG15 promotes HCV production.
In this study we investigate the role of USP18 in HCV
production.
Methods: We studied the effect of over-expression of
wild type (catalytically active) USP18 or an enzymatically
inactive mutant form of USP18 on HCV RNA replication and
viral production in JFH1 culture system. Levels of various
ISGs and of the critical miRNA 122 were assessed by real-
time PCR, and surface expression of the key HCV entry
receptor, CD81, were quantiﬁed by FACS.
Results: Over-expression of wild type and mutant USP18
increases HCV production at baseline (without IFN) and
blunts the anti-HCV activity of IFNa in the JFH1 infectious
system. While neither ISG expression nor miRNA 122 levels
were unaffected by overexpression of USP18, whether in the
presence or absence of IFNa, surface expression of CD81 was
increased following USP18 over-expression in Huh7.5 cells.
Conclusions: These data indicate that USP18 overexpression
leads to increased HCV production independent of its
catalytic activity, and in concert with increased surface
expression of CD81. Thus, USP18, one of the ISGs increased
in chronic HCV infection, stimulates HCV production and
likely contributes to treatment failure by promoting HCV
cell entry and blunting IFN anti-HCV activity.
OL-001 Clinico-epidemiological proﬁle of patients with
hepatitis C virus infection seen in private
practice clinics in Metro Manila
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Background: Hepatitis C virus (HCV) infection is a major
public health problem worldwide. In the Philippines, there
are few published data on the clinico-epidemiological proﬁle
of patients with HCV infection.
Methodology: Out-patient charts of patients seen from
October 2005 to November 2010 in private practice clinics of
3 gastroenterologists were reviewed. All patients with a pos-
itive anti-HCV and/or HCV-RNA were included. Clinical and
epidemiologic information were collected and analyzed.
Results: Of 49 patients included, 27 (55%) were males.
Mean age at diagnosis was 48.5 years. 26 patients had HCV
genotype data genotype 1 in 16 (61%) patients, genotype
2 in 8 (31%), genotype 4 in 2 (8%). The most common
risk factor was blood transfusion before 1990 identiﬁed in
18 (37%) patients. Other risk factors identiﬁed: injection
drug use (IDU) 7 (14%), hemodialysis (HD) 7 (14%), unknown
11 (23%), others 5 (12%). At presentation, 17 (35%) patients
had advanced HCV-related liver disease 13 cirrhosis only
and 4 hepatocellular carcinoma (HCC). Among 37 evaluable
treatment-naïve patients, 16 (43%) were ineligible for
treatment with advanced HCV-related liver disease (69%)
as the most common reason.
Conclusion: In this study, blood transfusion before 1990,
IDU, and HD were the most common risk factors for
HCV infection. Many patients had advanced liver disease
precluding eligibility for therapy. Screening for HCV among
those with a history of blood transfusion before 1990,
IDU, and HD may help identify HCV-infected patients
early allowing institution of antiviral therapy to prevent
progressive liver disease.
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Background: Hepatitis C viral (HCV) infection is the leading
cause of death due to liver disease. Additional agents are
